These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15117308)

  • 1. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.
    Staedke SG; Sendagire H; Lamola S; Kamya MR; Dorsey G; Rosenthal PJ
    Trop Med Int Health; 2004 May; 9(5):624-9. PubMed ID: 15117308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
    Happi CT; Gbotosho GO; Folarin OA; Akinboye DO; Yusuf BO; Ebong OO; Sowunmi A; Kyle DE; Milhous W; Wirth DF; Oduola AM
    Acta Trop; 2005 Sep; 95(3):183-93. PubMed ID: 16023986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria.
    Talisuna AO; Nalunkuma-Kazibwe A; Langi P; Mutabingwa TK; Watkins WW; Van Marck E; Egwang TG; D'Alessandro U
    Infect Genet Evol; 2004 Dec; 4(4):321-7. PubMed ID: 15374529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
    Mockenhaupt FP; Teun Bousema J; Eggelte TA; Schreiber J; Ehrhardt S; Wassilew N; Otchwemah RN; Sauerwein RW; Bienzle U
    Trop Med Int Health; 2005 Sep; 10(9):901-8. PubMed ID: 16135198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria.
    Kyabayinze D; Cattamanchi A; Kamya MR; Rosenthal PJ; Dorsey G
    Am J Trop Med Hyg; 2003 Sep; 69(3):247-52. PubMed ID: 14628939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda.
    Dorsey G; Dokomajilar C; Kiggundu M; Staedke SG; Kamya MR; Rosenthal PJ
    Am J Trop Med Hyg; 2004 Dec; 71(6):758-63. PubMed ID: 15642967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children.
    Tahar R; Basco LK
    Acta Trop; 2007 Aug; 103(2):81-9. PubMed ID: 17640607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda.
    Sendagire H; Kyabayinze D; Swedberg G; Kironde F
    Trop Med Int Health; 2005 Jun; 10(6):537-43. PubMed ID: 15941416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
    A-Elbasit IE; Alifrangis M; Khalil IF; Bygbjerg IC; Masuadi EM; Elbashir MI; Giha HA
    Malar J; 2007 Aug; 6():108. PubMed ID: 17686173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania.
    Eriksen J; Mwankusye S; Mduma S; Veiga MI; Kitua A; Tomson G; Petzold MG; Swedberg G; Gustafsson LL; Warsame M
    Trans R Soc Trop Med Hyg; 2008 Feb; 102(2):137-42. PubMed ID: 18082233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use.
    Nsimba B; Jafari-Guemouri S; Malonga DA; Mouata AM; Kiori J; Louya F; Yocka D; Malanda M; Durand R; Le Bras J
    Trop Med Int Health; 2005 Oct; 10(10):1030-7. PubMed ID: 16185238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of antifolate resistance in vitro and point mutations in dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum.
    Biswas S
    J Postgrad Med; 2004; 50(1):17-20. PubMed ID: 15047993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium falciparum: evaluation of a quantitative nucleic acid sequence-based amplification assay to predict the outcome of sulfadoxine-pyrimethamine treatment of uncomplicated malaria.
    Omar SA; Mens PF; Schoone GJ; Yusuf A; Mwangi J; Kaniaru S; Omer GA; Schallig HD
    Exp Parasitol; 2005 May; 110(1):73-9. PubMed ID: 15804381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment.
    Eriksen J; Mwankusye S; Mduma S; Kitua A; Swedberg G; Tomson G; Gustafsson LL; Warsame M
    Trans R Soc Trop Med Hyg; 2004 Jun; 98(6):347-53. PubMed ID: 15099990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria.
    Basco LK; Tahar R; Keundjian A; Ringwald P
    J Infect Dis; 2000 Aug; 182(2):624-8. PubMed ID: 10915101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré.
    Bonnet M; Roper C; Félix M; Coulibaly L; Kankolongo GM; Guthmann JP
    Malar J; 2007 May; 6():54. PubMed ID: 17477865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
    Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
    Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum and resistance to sulfadoxine-pyrimethamine in Sri Lanka.
    Hapuarachchi HC; Dayanath MY; Bandara KB; Abeysundara S; Abeyewickreme W; de Silva NR; Hunt SY; Sibley CH
    Am J Trop Med Hyg; 2006 Feb; 74(2):198-204. PubMed ID: 16474070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo.
    Ndounga M; Tahar R; Basco LK; Casimiro PN; Malonga DA; Ntoumi F
    Trop Med Int Health; 2007 Oct; 12(10):1164-71. PubMed ID: 17956498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes.
    Swarthout TD; van den Broek IV; Kayembe G; Montgomery J; Pota H; Roper C
    Trop Med Int Health; 2006 Oct; 11(10):1503-11. PubMed ID: 17002724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.